Medlive Technology Co., Ltd. (2192) AI Stock Analysis

• Market Cap: HK$9.19B
• Dividend Yield: 2.11%
• Average Volume (3M): 2.42M
• Price to Earnings (P/E): 26.2
• Beta (1Y): 1.45
• Revenue Growth: 29.81%
• EPS Growth: 10.40%
• Country: HK
• Employees: 747
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Distribution
• EPS (TTM): 0.23
• Shares Outstanding: 734,258,850
• 10 Day Avg. Volume: 1,729,570
• 30 Day Avg. Volume: 2,423,302
• PEG Ratio: 0.72
• Price to Book (P/B): 1.43
• Price to Sales (P/S): 12.28
• P/FCF Ratio: 78.46
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$15.00
• Price Target Upside: 19.90% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 67 Neutral
• Price Target: HK$15.00 ▲(19.90% Upside)

Medlive Technology Co., Ltd. demonstrates strong financial performance with robust revenue growth and a solid balance sheet, which are the most significant factors contributing to the score. However, technical indicators suggest a lack of momentum, and the valuation appears high, which tempers the overall score.

Medlive Technology Co., Ltd. Business Overview & Revenue Model

Company Description

Medlive Technology Co., Ltd., together with its subsidiaries, operates an online professional physician platform in Mainland China and internationally. Its precision marketing and corporate solution provides full service on its one-site platform, which includes project management, clinical monitoring, clinical data management, biostatistics, protocol design, medical monitoring, patient recruitment, and supporting system, as well as digital market research, electronic data capture, real-world studies, and application software development services. The company's medical knowledge solution offers medical education and clinical decision support, including licensing software to physicians, other registered users, such as other healthcare professionals and pharmaceutical companies. Its intelligent patient management solution provides chronic disease management services, comprising online patient consultation, prescription services, and patient management through Internet hospital; and condition-specific patient education services, which includes content development, application software development, and other related services. The company was formerly known as Kingyee Co., Limited and changed its name to Medlive Technology Co., Ltd. in 2021. Medlive Technology Co., Ltd. was founded in 1996 and is headquartered in Beijing, China.

How the Company Makes Money

Medlive Technology Co., Ltd. generates revenue through a combination of subscription fees, advertising, and partnership arrangements. Key revenue streams include subscription services for access to premium medical content and tools, which are utilized by healthcare professionals and institutions. The company also earns income from pharmaceutical and medical device companies through targeted advertising and sponsored content, which allow these firms to reach a highly specialized audience. Additionally, Medlive engages in partnerships with healthcare organizations to offer customized solutions and services, further contributing to its financial performance.

Medlive Technology Co., Ltd. Financial Statement Overview

Summary

Medlive Technology Co., Ltd. exhibits strong financial health with consistent revenue growth, efficient operational performance, and a robust balance sheet with low leverage. The company maintains healthy cash flows, although investment activities show some variability.

Income Statement

Medlive Technology Co., Ltd. demonstrates robust revenue growth, with Total Revenue increasing from 2019 to 2024. The Gross Profit Margin and Net Profit Margin have remained strong, reflecting stable and efficient cost management. Despite a decline in EBIT Margin from previous years, the EBITDA Margin remains healthy, indicating strong operational performance.

Balance Sheet

The company's Balance Sheet is solid with a high Equity Ratio, suggesting financial stability and low reliance on debt. The Debt-to-Equity Ratio is very low, indicative of minimal financial leverage. Return on Equity has shown a positive trend, highlighting effective use of shareholder funds.

Cash Flow

Cash flow analysis reveals consistent Free Cash Flow generation, with positive growth over time. The Operating Cash Flow to Net Income Ratio indicates strong cash-generating capability. However, fluctuations in Investing Cash Flow suggest potential volatility in investment activities.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	558.46M	412.00M	314.05M	284.44M	213.53M
Gross Profit	327.22M	251.34M	212.74M	200.73M	156.24M
EBITDA	121.35M	262.86M	144.56M	76.61M	110.37M
Net Income	315.15M	242.30M	117.32M	40.62M	85.20M
Balance Sheet
Total Assets	5.11B	4.89B	4.60B	4.12B	227.06M
Cash, Cash Equivalents and Short-Term Investments	4.15B	4.40B	4.22B	3.91B	147.09M
Total Debt	22.63M	8.19M	11.26M	13.17M	12.07M
Total Liabilities	253.56M	248.61M	171.31M	143.37M	75.64M
Stockholders Equity	4.80B	4.60B	4.40B	3.95B	151.41M
Cash Flow
Free Cash Flow	87.44M	69.34M	69.70M	42.47M	110.42M
Operating Cash Flow	108.32M	101.87M	77.19M	44.43M	111.05M
Investing Cash Flow	111.02M	-634.95M	-3.59B	-50.54M	13.00K
Financing Cash Flow	-197.89M	-133.13M	-22.38M	3.79B	-2.83M

Medlive Technology Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 12.51
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2192, the sentiment is Neutral. The current price of 12.51 is below the 20-day moving average (MA) of 13.32, below the 50-day MA of 14.14, and below the 200-day MA of 12.62, indicating a neutral trend. The MACD of -0.42 indicates Positive momentum. The RSI at 45.15 is Neutral, neither overbought nor oversold. The STOCH value of 22.98 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:2192.

Medlive Technology Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2607	72 Outperform	HK$75.85B	6.80	6.35%	2.64%	3.60%	47.33%
1099	68 Neutral	HK$56.70B	7.72	8.94%	4.06%	-2.68%	-21.45%
2192	67 Neutral	HK$9.19B	26.19	6.77%	2.11%	29.81%	10.40%
1931	65 Neutral	HK$14.56B	77.41	7.01%	1.02%	0.33%	-44.28%
9955	41 Neutral	HK$881.51M	-0.79	-35.52%	―	-43.86%	-217.25%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Medlive Technology Co., Ltd. Corporate Events

Medlive Technology Announces Interim Dividend for 2025

Medlive Technology Co., Ltd. announced an interim dividend of RMB 0.1166 per share for the six months ended 30 June 2025, with a payment date set for 25 September 2025. This announcement reflects the company’s financial health and commitment to providing returns to its shareholders, potentially strengthening its market position and investor confidence.

The most recent analyst rating on (HK:2192) stock is a Buy with a HK$16.50 price target. To see the full list of analyst forecasts on Medlive Technology Co., Ltd. stock, see the HK:2192 Stock Forecast page.

Medlive Technology Reports Strong Revenue Growth in H1 2025

Medlive Technology Co., Ltd. reported a 28.2% increase in revenue for the first half of 2025 compared to the same period in 2024, driven primarily by its precision marketing and corporate solutions segment. The company’s financial performance highlights a 5.9% increase in profit attributable to owners, indicating a stable growth trajectory and reinforcing its strong market position in the healthcare technology sector.

The most recent analyst rating on (HK:2192) stock is a Buy with a HK$16.50 price target. To see the full list of analyst forecasts on Medlive Technology Co., Ltd. stock, see the HK:2192 Stock Forecast page.

Medlive Technology Schedules Board Meeting for Interim Results

Medlive Technology Co., Ltd. has announced that its board of directors will meet on August 25, 2025, to review and approve the company’s interim results for the first half of the year ending June 30, 2025. The meeting will also consider the payment of an interim dividend, indicating potential financial distribution to shareholders.

Medlive Technology Updates Nomination Committee Terms

Medlive Technology Co., Ltd. has updated the terms of reference for its Nomination Committee, effective from June 30, 2025. The committee, which will consist of at least three directors with a majority being independent non-executive directors, is tasked with reviewing the board’s structure and composition annually. This move aims to ensure the board’s alignment with the company’s corporate strategy and enhance its governance by selecting qualified individuals for directorships.